Latest News-Zhongshan Kangfang Biological Medicine Co., LTD Mediaroom_Page

Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes

HONG KONG, Sept. 27, 2023 /PRNewswire/ -- Akeso, Inc. (the Company, Akeso, 9926.HK) announced tha...

2023-09-28 10:07 2093

Akeso Announced 2023 Interim Results: First Profit, Growing Sales of PD-1/CTLA-4 Bispecific Antibody and Priority Review of PD-1/VEGF

—During the reporting period, Akeso's revenue was RMB3,676.9 million, an increase of 2,154.4% from ...

2023-08-30 08:03 2578

Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-line PD-L1 Positive Advanced NSCLC

HONG KONG, Aug. 29, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced completion of pat...

2023-08-29 20:00 1892

Akeso Announced that Ivonescimab Granted Priority Review of NDA by China NMPA

HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial...

2023-08-25 20:00 2650

Akeso Announced NDA Acceptance of IL-12/lL-23 Monoclonal Antibody Ebdarokimab for Moderate-to-severe Plaque Psoriasis by China NMPA

HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial...

2023-08-24 20:00 2150

Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC

HONG KONG, Aug. 18, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced today that the fi...

2023-08-18 20:00 6503

The eClinical Medicine of Lancet Published Phase 2 Results of Ivonescimab for the Treatment of NSCLC

HONG KONG, Aug. 7, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial...

2023-08-07 12:29 2466

Akeso Inc. Published 2023 Interim Results Positive Profit Alert

HONG KONG, July 31, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial...

2023-07-31 12:33 4154

Promising 2-year updated data from cadonilimab presented at 2023 ASCO highlighting promising efficacy in PD-L1-negative patients

HONG KONG, June 6, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso") released two-year updated d...

2023-06-06 19:04 2428

NMPA accepted Akeso's ebronucimab (PCSK9) marketing application in two cardiovascular indications

HONG KONG, June 1, 2023 /PRNewswire/ -- Akeso Inc. (9926. HK, "Akeso") announced today thatChina's ...

2023-06-02 11:43 2527

Akeso Reported 2022 Annual Results

* Strong sales fully demonstrated Akeso's commercialization ability: Products sales totaledRMB1,1...

2023-03-16 08:26 4102

Patient Enrollment Completed for Phase III Clinical Trial of Akeso's Cadonilimab in Treatment of Gastric Cancer

HONG KONG, March 14, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that patient enrollment h...

2023-03-14 17:01 1966

Akeso Received First Tranche of US$300 Million Upfront Payment from Summit! Summit Is Accelerating Clinical Development of Ivonescimab

HONG KONG, Jan. 26, 2023 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company"), a comme...

2023-01-26 20:24 4071

China NMPA Approved Penpulimab for First-line Treatment of Locally Advanced or Metastatic Squamous NSCLC

HONG KONG, Jan. 15, 2023 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso"), a commercial-stage biop...

2023-01-16 08:55 2594

JITC publication of Akeso's Ligufalimab(CD47 monoclonal antibody) mechanism shows promising antitumor efficacy and favorable safety profile

HONG KONG, Dec. 11, 2022 /PRNewswire/ -- Akeso Inc. (9926. HK) ("Akeso") today announced that the J...

2022-12-12 12:59 2179

Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)

* Akeso Inc. to out-license to Summit Therapeutics exclusive rights to ivonescimab (PD-1/VEGF) fo...

2022-12-06 21:01 2720

Akeso's Ivonescimab (PD-1/VEGF Bispecific Antibody, AK112) Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China

* AK112 has now been granted three Breakthrough Therapy Designations for NSCLC * The only drug ca...

2022-11-14 08:00 2753

Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC

HONG KONG, Nov. 3, 2022 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") announced the patient...

2022-11-04 08:57 1992

Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022

HONG KONG, Oct. 30, 2022 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") released the Phase I...

2022-10-31 08:40 2034

Akeso's Ivonescimab (PD-1/VEGF BsAbs) Granted Breakthrough Therapy Designation by China NMPA for the Treatment of Advanced NSCLC

HONG KONG, Oct. 20, 2022 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso"), a China-based biopharmac...

2022-10-21 09:15 2423